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ABSTRACT
Shengmai San (SMS) is a well-known traditional Chinese medicine formula prescribed for patients with coronary heart disease
(CHD). Insulin resistance is the most likely explanation for the development and progression of this disease. To investigate the effect
of SMS on high-fat diet-induced insulin resistance, inflammatory cytokine production and oxidative stress, male Wistar rats were
fed with low-fat control diet, high-fat diet and high-fat diet supplemented with 4% SMS for eight weeks. An oral glucose tolerance
test was conducted in the seventh week. Rats fed the SMS diet had significantly lower plasma fructosamine concentration ( p < 0.05)
and tended to have lower (p < 0.1) AUC values of plasma glucose and insulin concentrations after glucose challenge, compared to
those fed the high-fat diet. Moreover, SMS reduced TNF-α and lipid peroxidation levels in the liver and heart. However, SMS had
no effect on fasting plasma concentrations of glucose, insulin, triglyceride, non-esterified fatty acids, total cholesterol, HDL-cholesterol and insulin resistance index (homeostasis model assessment; HOMA) in rats. Our results show that SMS may have little or no
significant effect on reducing insulin resistance, but display anti-oxidative and anti-inflammatory properties.
Key words: shengmai san, insulin resistance, high-fat diet, TNF-α, rats

INTRODUCTION
Various clinical studies have shown that chronic
elevated plasma glucose and insulin are associated with
an increased risk for coronary heart disease (CHD), and
insulin resistance is the most likely explanation for the
development and progression of this disease (1). With
insulin resistance, endothelium may impair vasodilator
nitric oxide (NO) release and increase oxidative stress
that may damage endothelial function(1,2). In addition,
increased circulatory levels of inflammatory cytokine,
such as tumor necrosis factor-alpha (TNF-α), have been
shown to be positively associated with insulin resistance,
suggesting that the inflammatory factors may potentiate
* Author for correspondence. Tel: +886-4-22053366 ext. 7526;
Fax: +886-4-22062891; E-mail: htyao@mail.cmu.edu.tw;
E-mail: tkyeh@nhri.org.tw

the cardiovascular risk factor’s role of insulin resistance (3). Indeed, TNF-α is over-expressed in patients with
heart failure (4) and involved in a number of etiologies of
cardiac disease possibly due to increased oxidative stress
and cardiac myocyte injury(5). Besides a change of lifestyle, the effective administration of dietary supplements
or medicinal herbs with anti-inflammatory and/or antioxidative activities is considered a promising approach to
reduce insulin resistance and inflammation, thus lowering
the risk of developing CHD(6,7).
Traditional Chinese medicines (TCM) are widely
used in Asia for treating a variety of disorders. For
convenience, the traditional decoction process has been
improved by concentrating the extracts and by formulating of powdered dosage forms. Shengmai San (SMS),
which comprises the medicinal herbs of Panax ginseng C.
A. Meyer, Schisandra chinensis Baill., and Ophiopogon
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japonicus Ker-Gawl (2 : 1 : 2), is a well-known TCM with
long-time clinical use. It is usually prescribed for patients
with CHD and has been found to display anti-oxidative
effects(8). A recent clinical study has shown that the longterm consumption of SMS as a supplement is safe and can
accelerate the recovery of heart function in patients(9).
Moreover, studies have also shown that conventional
treatment with shengmai injection (added to 5% dextrose
or normal saline as intravenous infusions) for 3-4 weeks
can improve not only vascular endothelial and heart functions(10), but also insulin resistance in patients with heart
disease (11). Although each herbal component in SMS has
been shown to exert beneficial effects on reducing the
risk of developing CHD, such as reducing insulin resistance (12) and increasing anti-oxidative and anti-inflammatory activities(13-15), it is not known whether SMS can
ameliorate insulin resistance and inflammatory reaction
when administered orally.
High-fat diets have been associated with insulin
resistance, a risk factor for both Type II diabetes and
heart disease in humans (16). The symptoms of insulin
hypersecretion and glucose intolerance after glucose
challenge have also been demonstrated in rats fed the
high-fat diets (17). The aim of this study is to investigate
the effect of SMS supplementation on insulin resistance,
TNF-α level and oxidative stress in the liver and heart of
rats fed a high-fat diet. The dosage of 4% SMS in the diet
was chosen because it had been shown to significantly
reduce hepatic lipid contents and lipid peroxidation(18).

MATERIALS AND METHODS
I. Shengmai San
Shengmai San (SMS) concentrated powder was
obtained from Sheng Chang Pharmaceutical (Taipei,
Taiwan). SMS comprises the medicinal herbs of Panax
ginseng C. A. Meyer, Schisandra chinensis Baill. and
Ophiopogon japonicus Ker-Gawl (2 : 1 : 2). The yield
from water extraction was 16% (w/w). In the preparation
used in this study, the SMS powder contained 11.9 µg/g of
ginsenoside Rf, 13.7 µg/g of ginsenoside Rg 2 , 6.5 µg/g of
ginsenoside Rg3, < 0.2 µg/g of ginsenoside Rh1, 8.6 µg/g
of gomisin A, 20.5 µg/g of schizandrin and < 0.2 µg/g of
methyl-ophioponanone B, respectively, determined by
LC/MS(18).
II. Animals and Treatment
Twenty-four 9-week-old male Wistar rats (BioLASCO
Taiwan Co., Ltd., Ilan, Taiwan) were randomly divided
into three groups: (a) the control group (CTR), rats in
this group were fed a standard laboratory rat diet; (b) the
high-fat diet group (HF), rats in this group were fed a
high-fat diet; (c) the SMS group (SMS), rats in this group
were fed a high-fat diet containing 4% SMS (w/w). The

high-fat diet contained 85% standard laboratory rat diet
and 15% lard (w/w). The cholesterol content in the highfat diet was 0.015%. The rats were housed in individual
cages in a room kept at a temperature of 23 ± 1°C and
relative humidity of 60 ± 5% with a 12-h light and dark
cycle. Food and drinking water were available ad libitum
for eight weeks. Food intake was measured every two days
and body weight was measured once a week. After seven
weeks of feeding, an oral glucose tolerance test (OGTT)
was conducted. At the end of the 8-week experimental
period, the rats were fasted for 12 h prior to being sacrificed (at 10:00 AM). The rats were killed by exsanguination via the abdominal aorta, while under carbon dioxide
(70%/30%, CO2/O2) anesthesia. Heparin was used as the
anticoagulant. Plasma was separated from the blood by
centrifugation (1,750 ×g) at 4°C for 20 min. The liver, heart
and adipose tissues (epididymal and abdominal) from each
animal were excised, weighed and immediately stored
frozen at -80°C.
All animal experiments were performed based
on the animal ethics guidelines of the Institutional
Animal Ethics Committee in the Taiwan National Health
Research Institute (NHRI).
III. Oral Glucose Tolerance Test (OGTT)
After the seventh week of the feeding period, the
rats were deprived of food for 12 h, and then a 2 g/kg
dose of glucose solution was administered intragastrically. Serial blood samples were collected from the tail
vein of each rat immediately before dosing (0 min) and at
30, 60, 120 and 180 min after dosing. Plasma was separated from the blood samples and analyzed for glucose
and insulin concentrations according to the methods
described below. The area under the plasma glucose
or insulin concentration versus time curve (AUC) was
calculated using the trapezoidal method.
IV. Insulin Resistance Measurement
The homeostasis model assessment (HOMA) was
expressed as an index of insulin resistance (19). It was
calculated by the formula HOMA = fasting glucose
[mmol/L] × fasting insulin [µU/mL] / 22.5.
V. Determination of Plasma Lipids, Fructosamine, Glucose,
Insulin, Total Antioxidant Status and Aminotransferase
Activity
Plasma concentrations of glucose, total cholesterol and triglyceride were determined by the enzymatic
methods provided by the kits purchased from Audit
Diagnostics (Cork, Ireland). The concentrations of nonesterified fatty acid (NEFA) and insulin in plasma were
determined by the enzymatic methods provided by the
kits purchased from Waco Pure Chemical Industries,
Ltd. (Osaka, Japan) and Mercodia (Uppsala, Sweden),
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respectively. High density lipoprotein (HDL) cholesterol
was measured after the removal of very low density lipoprotein (VLDL) and LDL cholesterol by heparin-manganese precipitation (Randox Laboratories, Crumlin, U.K.).
Plasma total antioxidant status (TAS) and the activities
of aspartate aminotransferase (AST) and alanine aminotransferase (ALT) were determined using the commercial
kits from Randox Laboratories (Antrim, U.K.). Fructosamine was determined by a colorimetric method using the
kit purchased from Hospitex Diagnostic (Firenze, Italy).
VI. Determination of Liver Lipids
Lipids were extracted from the liver by the method
of Folch et al.(20) and solubilized in Triton X-100
according to the method of Carlson and Goldfard (21). The
hepatic total cholesterol, triglyceride and NEFA contents
were assayed enzymatically by the same method, as
described above.
VII. Determination of Hexokinase, Glucose-6-Phosphatase
and Glutathione Peroxidase (GSH-Px) Activities
Tissues were homogenized in ice-cold 1.15% KCl
to obtain a final 10% (w/v) solution. The homogenates
were immediately centrifuged at 10,000 × g for 15 min
at 4°C. The resulting supernatant was used for the assay
of enzyme activity. The protein content was determined
using a BCA protein assay kit (Pierce, Rockford, IL, USA).
Hepatic hexokinase and glucose-6-phosphatase
were assayed according to the method of Nagayama et
al.(22).The enzyme activities were expressed as the rate
of NADPH and inorganic phosphate formation, respectively. GSH-Px activity was determined spectrophotometrically according to the method of Mohandas et al.(23)
and expressed as nanomoles of NADPH decrease per
minute per milligram of protein.

VIII. Determination of Lipid Peroxidation, Glutathione and
Tumor Necrosis Factor-Alpha (TNF-α) Levels in the Liver
and Heart
GSH was determined by a LC/MS method reported
previously(24). Lipid peroxidation, as measured by thiobarbituric acid reactive substances (TBARS), in plasma
and tissues were assessed by the methods of Yagi(25) and
Uchiyama and Mihara (26), respectively. The calibration
curve of a 1,1,3,3-tetramethoxypropane (Sigma) was used
to determine the concentrations of TBARS in samples.
Fluorescence was measured at excitation and emission
wavelengths of 515 nm and 553 nm, respectively. The
concentrations of TNF-α in plasma and tissues (liver
and heart) were determined by immunoassay, according
to the method provided by R&D Systems, Inc. (Minneapolis, MN, USA).
IX. Statistical Evaluation
Statistical differences among the groups were calculated using one-way ANOVA (SAS Institute, Cary, NC,
USA) and were considered to be significant at p < 0.05,
as determined by Duncan’s new multiple-range test.

RESULTS
As shown in Table 1, after 8 weeks of feeding, there
was no difference in the body weight and the relative
liver and heart weights among the animals in the three
groups. Lower daily food intake and higher adipose
tissue weight were observed in rats of the HF and SMS
groups, compared to rats of the CTR group. There was no
difference in adipose tissue weight and daily food intake
between the rats of the HF and SMS groups.
Figures 1A and 1C show the plasma concentrations

Table 1. Body weight, tissue weight and food intake of rats of the CTR, HF and SMS groups after eight weeks of feeding regimena
Dietb

SMS

363.6 ± 17.9

364.3 ± 17.1

365.4 ± 17.0

Final body weight (g)

490.6 ± 35.5

523.7 ± 30.0

512.2 ± 22.2

Food intakec (g/day)

31.2 ± 2.3

26.5 ± 1.3*

27.3 ± 1.7*

2.9 ± 0.2

2.8 ± 0.1

2.9 ± 0.2

0.28 ± 0.02

0.28 ± 0.02

0.30 ± 0.02

2.8 ± 0.5

4.6 ± 1.2*

5.2 ± 0.9*

Heart (g/100g b.w.)
Adipose tissue (g /100g b.w.)

Values are mean ± SD of eight rats in each group.
CTR: control group; HF: high-fat diet group; SMS: high-fat diet with SMS group.
c
Food intake was measured every two days over a period of 8 weeks.
*Significantly different from the CTR group at p < 0.05.
b

HF

Initial body weight (g)

Liver weight (g/100g b.w.)

a

CTR
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of glucose and insulin in rats of the CTR, HF and SMS
groups. Figures 1B and 1D show the area under the
plasma concentrations of glucose and insulin versus time
curve (AUC) values of rats in the three groups. After
glucose challenge, the plasma glucose concentration of
rats in the HF group was significantly higher than that of
the CTR group at 120 and 180 min. For rats in the SMS
group, the plasma glucose concentration was significantly higher than that of the CTR group at 180 min after
the challenge. The plasma insulin concentration of rats
in the HF group was significantly higher than that of the
CTR group at all time points. There was no significant
difference in plasma glucose and insulin concentration
between the rats of the HF and SMS groups, except at
120 min when plasma glucose and insulin concentration
was lower in the SMS group than that of the HF group
(Figure 1A and 1C). The plasma glucose AUC value of
rats in the HF group was significantly higher than that of
the CTR group. No significant difference in the plasma
glucose AUC values between the rats of the HF and SMS
groups was observed (Figure 1B). The plasma insulin
AUC values of rats in the HF and SMS groups were
both significantly higher than that of the CTR group.
However, there was no significant difference between

(A)

(B)
200

Glucose AUC (0-180 min)

*

Glucose (mg/dl)

#
160
* *
120
80
40
0

0

30

60
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900
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Insulin AUC (0-180 min)

*

450

#

* *

*
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*

24000
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8000

CTR
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SMS

100000
*

* *
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300

40000

0

(min)

(C)

Insulin (pmol/l)

the plasma insulin AUC values of the rats in the HF and
SMS groups (Figure 1D). These results indicated that rats
fed the high-fat diet had developed insulin resistance and
glucose intolerance. Rats in the SMS group tended to
have lower plasma glucose (-5.7%, p = 0.064) and insulin
(-23.7%, p = 0.068) AUC values, compared to that of the
HF group, suggesting that SMS may have a mild effect
on reducing insulin resistance and glucose intolerance.
Table 2 shows the plasma parameters of rats in the
CTR, HF and SMS groups. Rats in the HF and SMS groups
had significantly higher glucose, insulin, fructosamine and
HOMA levels than those of the CTR group. Plasma fructosamine level of rats in the SMS group was significantly
lower than that of the HF groups. However, there were no
significant differences in glucose, insulin and HOMA
levels between the rats in the HF and SMS groups. No
significant change in the concentrations of plasma lipids
(total cholesterol, HDL-cholesterol, triglyceride and
NEFA), total antioxidant status (TAS) and lipid peroxide
(TBARS), aminotransaminases (AST and ALT; data not
shown) were observed among the rats in the three groups.
Plasma TNF-α was not detected in rats of all three groups.
Table 3 shows the activities of hexokinase and
glucose-6-phosphatase and the concentration (mg/g of

60

120

180

(min)

80000
*
60000

40000

20000

0

CTR

HF

SMS

Figure 1. Plasma concentrations of glucose and insulin in rats of the CTR, HF and SMS groups after a 2 g/kg glucose-loading dose. Results are
mean ± SD of eight rats in each group. *HF vs. CTR group, p < 0.05. #HF vs. SMS group, p < 0.05. AUC: Area under the plasma concentration
of glucose or insulin vs. time curve.
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liver) of triglyceride, cholesterol and NEFA in the liver
of rats in the CTR, HF and SMS groups. Rats of the HF
and SMS groups had significantly higher triglyceride level
and glucose-6-phosphatase activity than that of the CTR
group. There was no significant difference in the triglyceride level and glucose-6-phosphatase activity between
the rats in the HF and SMS groups. There was also no
significant difference in the cholesterol and NEFA levels
and hexokinase activity among the rats in the three groups.
The activities of GSH-Px and concentrations of

GSH, TBARS and TNF-α in the liver and heart are shown
in Table 4. In the liver, rats of the HF group had significantly higher TBARS, GSH and TNF-α concentrations
and GSH-Px activity than that of the CTR group. Significantly reduced TBARS and TNF-α concentrations and
GSH-Px activity were observed in the rats of the SMS
group, compared to that of the HF group. In the heart,
there was no difference in TBARS, GSH and TNF-α
concentrations and GSH-Px activity between the rats of
the HF and CTR groups. However, significantly lower

Table 2. Plasma parameters of rats of the CTR, HF and SMS groups after eight weeks of feeding regimena
Dietb

CTR

HF

SMS

Glucose (mg/dL)

127.1 ± 5.5

150.6 ± 7.3*

148.4 ± 16.7*

Insulin (pmol/L)

112.2 ± 48.3

690.2 ± 340.1*

679.7 ± 400.1*

Fructosamine (µmol/L)

216.2 ± 45.8

347.8 ± 40.4*

277.6 ± 30.2*,#

Total cholesterol (mg/dL)

70.9 ± 9.5

81.7 ± 14.3

80.8 ± 10.8

Triglyceride (mg/dL)

61.8 ± 18.4

69.8 ± 13.7

67.3 ± 19.8

HDL-cholesterol(mg/dL)

25.4 ± 2.9

28.5 ± 4.9

27.0 ± 2.6

NEFA (mEq/mL)

0.38 ± 0.08

0.41 ± 0.14

0.38 ± 0.07

1.5 ± 0.9

2.0 ± 0.9

1.7 ± 0.8

TAS (mmol/dL)

0.97 ± 0.09

0.88 ± 0.23

0.90 ± 0.18

HOMA-IR index

3.5 ± 1.2

37.3 ± 10.3*

36.1 ± 14.2*

TBARS (nmol/mL)

a

Values are mean ± SD of eight rats in each group.
CTR: control group; HF: high-fat diet group; SMS: high-fat diet with SMS group.
*Significantly different from the CTR group at p < 0.05.
#Significantly different from the HF group at p < 0.05.

b

Table 3. Hepatic lipid concentrations and enzyme activities of rats of the CTR, HF and SMS groups after eight weeks of feeding regimena
Diet b

CTR

HF

SMS

Cholesterol (mg/g)

2.4 ± 0.3

2.8 ± 0.7

2.7 ± 0.7

Triglyceride (mg/g)

10.1 ± 2.7

23.8 ± 10.8*

20.3 ± 8.6*

4.7 ± 1.1

5.2 ± 2.4

3.9 ± 1.8

46.9 ± 6.0

42.4 ± 8.7

45.8 ± 6.5

288.7 ± 69.3

444.7 ± 63.1*

429.2 ± 23.7*

6.2 ± 1.5

10.7 ± 2.4*

9.5 ± 1.2*

Lipids

NEFA (mEq/g)
Enzyme activities c
Hexokinase
Glucose-6-phosphatase
Glucose-6-phosphatase/ Hexokinase
a

Values are mean ± SD of eight rats in each group.
CTR: control group; HF: high-fat diet group; SMS: high-fat diet with SMS group.
c
Enzyme activities are expressed as nmol/min/mg protein.
*Significantly different from the CTR group at p < 0.05.
b
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Table 4. TBARS, GSH and TNF-α concentrations and GSH-Px activity in the liver and heart of rats of the CTR, HF and SMS groups after
eight weeks of feeding regimena
Liver

Dietb

Heart

CTR

HF

SMS

CTR

HF

SMS

215.6 ± 22.8

255.2 ± 30.9*

196.3 ± 25.7#

382.4 ± 120.8

356.4 ± 41.2

296.4 ± 30.6*#

23.3 ± 8.6

41.9 ± 5.9*

45.4 ± 8.5*

14.0 ± 3.1

15.5 ± 1.5

GSH-Px (nmol/min/mg protein)

735.9 ± 90.6

871.2 ± 45.5*

770.4 ± 61.5#

193.1 ± 16.8

195.2 ± 18.3

174.9 ± 15.7*#

TNF-α (ng/mg protein)

159.9 ± 23.2

207.3 ± 21.6*

180.9 ± 11.5#

417.9 ± 53.2

428.5 ± 47.9

302.1 ± 53.4*#

TBARS (pmol/mg protein)
GSH (nmol/mg protein)

13.9 ± 1.5

a

Values are mean ± SD of eight rats in each group.
CTR: control group; HF: high-fat diet group; SMS: high-fat diet with SMS group.
*Significantly different from the CTR group at p < 0.05.
#Significantly different from the HF group at p < 0.05.

b

TBARS and TNF-α concentrations and GSH-Px activity
were observed in rats of the SMS group, compared to that
of the CTR and HF groups.

DISCUSSION
In our previous study, SMS was shown to reduce
hepatic lipids and lipid peroxidation in rats fed on a highcholesterol diet(18). However, it is not known whether
SMS can reduce insulin resistance, which is the most
likely explanation for the development and progression of CHD. In this study, we evaluated this possibility
using another animal model of insulin resistance which is
induced by a high-fat diet. Our results demonstrated that
the beneficial effect of SMS on glucose control was mild,
but SMS exerted anti-oxidative and anti-inflammatory
properties in rats that were fed the high-fat diet.
Liver plays an important role in maintaining plasma
glucose concentration through the regulation of metabolic pathways of gluconeogenesis and glycolysis (27).
Studies indicate that fat accumulation in the liver can
reduce the insulin sensitivity of the liver cells and
defect in insulin suppression of hepatic glucose production(28,29). In the rats that were fed the high-fat diet, fat
accumulation in liver may lead to insulin resistance.
This impairment of insulin action in rats has been partly
attributed to the inflammatory response elevated by highfat diet, such as an overproduction of TNF-α (30). Similar
to the results of previous studies, our results showed that
rats fed the HF diet had increased TNF-α level (Table 4)
and up-regulated glucose-6-phosphatase activity (Table
3) in the liver. These results were accompanied with
higher fasting plasma glucose and insulin concentration
and hyperinsulinemia in response to glucose challenge.
Moreover, a higher HOMA value was also found in rats
that were fed the HF diet, indicating that insulin resistance had been developed in those animals. Although the
rats that were fed the SMS diet had no effect on fasting

plasma glucose and insulin concentration as well as
insulin resistance (HOMA), it had reduced plasma fructosamine level, a glycated plasma protein which reflects
average blood glucose concentration and monitoring
glucose control over the previous 1 - 3 weeks. After the
glucose challenge (OGTT), the rats of the SMS group
had lower plasma concentrations of insulin (at 30 and
120 min) and glucose (at 120 min) than the rats of the HF
group. Lower AUC values of plasma glucose ( p = 0.064)
and insulin ( p = 0.068) were also observed in SMS group
than those in the HF group, despite the fact that these
differences were not statistically significant (Figure 1B
and 1D). Furthermore, the TNF-α level in the liver of
rats in the SMS group was lower than that of the rats in
the HF group (Table 4). These results suggested that the
beneficial effect of SMS on glucose control was mild and
might be partially attributed to a lower hepatic TNF-α
level. However, in this study, the extent of hepatic TNF-α
level lowering (-12.7%) by SMS might not reach the
threshold to affect insulin resistance for no significant
change on HOMA value was observed.
In addition to insulin resistance, TNF-α is also a
signal to trigger oxidative stress in the cells. TNF-α is
up-regulated in patients with non-alcoholic fatty liver
disease (NAFLD)(31) and cardiac disease (4), which may
lead to increased ROS production and lipid peroxidation
in these tissues. Previous studies indicated that SMS has
protective effects on the prevention of chemical-induced
oxidative damage (e.g. adriamycin, carbon tetrachloride, hydrogen peroxide). Under severe oxidative stress,
reduced lipid peroxidation and increased enzymatic (i.e.
GSH-Px) and/or non-enzymatic (i.e. GSH) antioxidants
are responsible for the therapeutic effect of SMS(32,33).
In the present study, higher hepatic TBARS level was
observed in the rats of the HF group than that of the
CTR group, indicating that a high-fat diet resulted in an
increase of lipid peroxidation in the liver. In addition,
GSH level and GSH-Px activity, which act as antioxidants and are known to be up-regulated under oxidative
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stress, was increased in the liver of rats that were fed the
HF diet. This result might be explained by an adaptive
mechanism in response to the oxidative stress in liver (34).
However, in the heart, there was no difference in TBARS
and GSH levels and GSH-Px activity between the rats
of the HF and CTR groups. These results indicated that
the liver was more sensitive to oxidative stress induced
by high-fat diet than the heart. It is interesting to note
that SMS reduced TBARS level and GSH-Px activity in
both liver and heart, suggesting that SMS might reduce
oxidative stress in these tissues. Moreover, reduced
TBARS level in liver and heart by SMS was also accompanied with a lower TNF-α level in these tissues. Since
TNF-α plays a central role in initiating and sustaining
the inflammatory response and increase oxidative stress
in tissues (5), it is proposed that reduced TNF-α levels in
the liver and heart by SMS might result in a lower level
of oxidative stress in these tissues. Our results supported
previous findings showing that SMS had beneficial
effects on reducing tissue injury caused by oxidative
damage (8,33).
In contrast to our previous result that SMS reduced
hepatic triglyceride and cholesterol levels in rats that
were fed with cholesterol-enriched diet (0.5% cholesterol
and 0.1% cholic acid)(18), in the present study, however,
administration of SMS had no effect on liver lipids in
rats that were fed the high-fat diet. The possible explanation for this discrepancy may have been due to the
differences in the amount of the cholesterol provided by
the experimental diets. It has been shown that rats that
were fed a high cholesterol diet increase the hepatic
cholesterol content, and that may result in the increased
triglyceride biosynthesis and reduced fatty acid oxidation(35). When rats were fed the high-cholesterol diet,
increased excretion of fecal bile acid, the primary route
of endogenous degradation of cholesterol, by SMS is
suggested to be responsible for its hepatic lipids-lowering
effect (18). However, in the present study, when rats were
fed the high-fat diet (containing only 0.015% cholesterol)
without additional cholesterol supplementation, SMS
failed to change the level of hepatic lipids. These results
indicated that SMS may only reduce high-cholesterol
diet-induced lipogenesis, but has no effect on high-fat
diet-induced fat accumulation in liver.
Recent clinical studies have shown that conventional treatment with shengmai injection for 3 - 4 weeks
can improve not only vascular endothelial and heart
functions (10), but also insulin resistance in patients with
heart disease (11). However, when administered orally
with shengmai capsule, long-term application (6 months)
was required to accelerate the recovery of heart function(36). These results imply that certain active components in SMS can improve insulin resistance and heart
functions. However, these active components may
have limited systemic exposure when administered
orally. Indeed, studies indicated that saponins in Panax
ginseng may have low oral bioavailability due to poor

membrane permeability and active biliary excretion(37),
even though Panax ginseng has been reported to have
beneficial effects on reducing insulin resistance (12) and
inflammation(13). Schizandrin, the most abundant (20.5
µg/g) active component in SMS, is the main effective
orally-absorbed ingredient of Fructus Schisandrae and
its oral absorption can be enhanced by some ingredients
in SMS(38). Schizandrin has been demonstrated to have
anti-oxidative and anti-inflammatory activities (39,40)
and is believed to be the major myocardial protective
component in SMS(41). Therefore, in this study, lower
TNF-α and TBARS levels in liver and heart caused by
SMS might be partially related to schizandrin. However,
in addition to schizandrin, other constituents in SMS
should also be considered as SMS is a composite formula
comprising of three herbal components. Therefore, the
synergism effect among herbal components may have
occurred, as seen in other TCM(42).
In summary, our results show that SMS supplementation may have little or no effect on reducing insulin
resistance, but display anti-oxidative and anti-inflammatory properties in rats.

ACKNOWLEDGMENTS
This study was financially supported by grant aid
from the China Medical University (CMU98-N1-11) and
the National Health Research Institutes of Taiwan.

REFERENCES
1. Potenza, M. A. and Montagnani, M. 2008. Abnormal
insulin signaling: early detection of silent coronary
artery disease-erectile dysfunction? Curr. Pharm. Des.
14: 3737-3748.
2. Oudot, A., Behr-Roussel, D., Compagnie, S., Caisey,
S., Le Coz, O., Gorny, D., Alexandre, L. and Giuliano,
F. 2009. Endothelial dysfunction in insulin resistant
rats is associated with oxidative stress and cox pathway
dysregulation. Physiol. Res. 58: 499-509.
3. Anuurad, E., Tracy, R. P., Pearson, T. A., Kim, K. and
Berglund, L. 2009. Synergistic role of inflammation
and insulin resistance as coronary artery disease risk
factors in African Americans and Caucasians. Atherosclerosis 205: 290-295.
4. Balakumar, P. and Singh, M. 2006. Anti-tumour
necrosis factor-alpha therapy in heart failure: future
directions. Basic Clin. Pharmacol. Toxicol. 99: 391-397.
5. Kaur, K., Sharma, A. K., Dhingra, S. and Singal, P. K.
2006. Interplay of TNF-alpha and IL-10 in regulating
oxidative stress in isolated adult cardiac myocytes. J.
Mol. Cell Cardiol. 41: 1023-1030.
6. Berk, B. C. 2007. Novel approaches to treat oxidative
stress and cardiovascular diseases. Trans. Am. Clin.
Climatol. Assoc. 118: 209-214.

47
Journal of Food and Drug Analysis, Vol. 19, No. 1, 2011

7. Kalantar-Zadeh, K., Anker, S. D., Horwich, T. B. and
Fonarow, G. C. 2008. Nutritional and anti-inf lammatory interventions in chronic heart failure. Am. J.
Cardiol. 101: 89E-103E.
8. Ko, K. M., Mark, D. H. F., Yin, T. K. and Yan, Y.
Q. 2002. Pharmacological studies on Shengmai San.
In: K.M. Ko and R. Hardman (Eds.), Shengmai San.
Taylor & Francis, pp. 17-40. London and New York.
9. Zhang, Y. C., Chen, R. M., Lu, B. J., Zhao, M. H. and
Rong, Y. Z. 2009. Influence of shengmai capsule on
recovery of living capacity in patients after myocardial
infarction. Chin. J. Integr. Med. 15: 333-336.
10. Zhang, Y. C., Lu, B. J., Zhao, M. H., Rong, Y. Z. and
Chen, R. M. 2008. Effect of Shengmai injection on
vascular endothelial and heart functions in patients
with coronary heart disease complicated with diabetes
mellitus. Chin. J. Integr. Med. 14: 281-285.
11. Yang, Y., Yin, C.Y., Yang, Y. and Zhao, S. 2004. Clinical study of effect of shengmai injection on insulin
resistance in patients with coronary heart disease. Acta
Acad. Med. Wuhan. 13: 363-364.
12. Liu, T. P., Liu, I. M., and Cheng, J. T. 2005. Improvement of insulin resistance by panax ginseng in fructose-rich chow-fed rats. Horm. Metab. Res. 37: 146-151.
13. Rhule, A., Navarro, S., Smith, J. R. and Shepherd, D.
M. 2006. Panax notoginseng attenuates LPS-induced
pro-inf lammatory mediators in RAW264.7 cells. J.
Ethnopharmacol. 106: 121-128.
14. You, J. S., Pan, T. L., and Hou, Y. C. 2006. Schisandra
chinensis protects against adriamycin-induced cardiotoxicity in rats. Chang Gung Med. J. 29: 63-70.
15. Kou, J., Sun, Y., Lin, Y., Cheng, Z., Zheng, W., Yu,
B. and Xu, Q. 2005. Anti-inflammatory activities of
aqueous extract from Radix Ophiopogon japonicus and
its two constituents. Biol. Pharm. Bull. 28: 1234-1238.
16. Lovejoy, J. C. 1999. Dietary fatty acids and insulin
resistance. Curr. Atheroscler. Rep. 1: 215-220.
17. Esposito, E., Iacono, A., Bianco, G., Autore, G., Cuzzocrea, S., Vajro, P., Canani, R. B., Calignano, A., Raso,
G. M. and Meli, R. 2009. Probiotics reduce the inflammatory response induced by a high-fat diet in the liver
of young rats. J. Nutr. 139: 905-911.
18. Yao, H. T., Chang, Y. W., Chen, C. T., Chiang, M. T.,
Chang, L. and Yeh, T. K. 2008. Shengmai San reduces
hepatic lipids and lipid peroxidation in rats fed on a
high-cholesterol diet. J. Ethnopharmacol. 116: 49-57.
19. Matthews, D. R., Hosker, J. P., Rudenski, A. S., Naylor,
B. A., Treacher, D. F. and Turner, R. C.1985. Homeostasis model assessment: insulin resistance and betacell function from fasting plasma glucose and insulin
concentrations in man. Diabetologia 28: 412-419.
20. Folch, J., Lees, M. and Sloane-Stanley, G. M. 1957. A
purification of total lipid from animal tissue. J. Biol.
Chem. 226: 497-509.
21. Carlson, E. and Goldford, S. 1979. A sensitive enzymatic method for determination of free and esterified
tissue cholesterol. Clinica. Chimica. Acta. 79: 575-582.

22. Nagayama, F., Ohshima, H. and Umezawa, K. 1972.
Distribution of glucose-6-phosphate metabolizing
enzymes in fish. Nippon Suisan Gakkaishi 38: 589-593.
23. Mohandas, J., Marshall, J. J., Duggin, G. G., Horvath,
J. S. and Tiller, D. J. 1984. Low activities of glutathione-related enzymes as factors in the genesis of
urinary bladder cancer. Cancer Res. 44: 5086-5091.
24. Yao, H. T., Lin, P., Chang, Y. W., Chen, C. T., Chiang,
M. T., Chang, L., Kuo, Y. C., Tsai, H. T. and Yeh, T.
K. 2009. Effect of taurine supplementation on cytochrome P450 2E1 and oxidative stress in the liver and
kidneys of rats with streptozotocin-induced diabetes.
Food. Chem. Toxicol. 47: 1703-1709.
25. Yagi, K. 1976. A simple fluorimetric assay for lipid
peroxidation in plasma. Biochem. Med. 15: 212-216.
26. Uchiyama, M. and Mihara, M. 1978. Determination
of malonaldehyde precursor in tissue by thiobarbituric
acid test. Anal. Biochem. 86: 271-278.
27. Newsholme, E. A. and Dimitriadis, G. 2001. Integration of biochemical and physiologic effects of insulin
on glucose metabolism. Exp. Clin. Endocrinol.
Diabetes. 109: 122-134.
28. Yu, A. S. and Keeffe, E. B. 2002. Nonalcoholic fatty
liver disease. Rev. Gastroenterol. Disord. 2: 11-19
29. Seppala-Lindroos, A., Vehkavaara, S., Hakkinen, A.
M., Goto, T., Westerbacka, J., Sovijarvi, A., Halavaara,
J. and Yki-Jarvinen, H. 2002. Fat accumulation in the
liver is associated with defects in insulin suppression
of glucose production and serum free fatty acids independent of obesity in normal men. J. Clin. Endocrinol.
Metab. 87: 3023-3028.
30. Flanagan, A. M., Brown, J. L., Santiago, C. A., Aad,
P. Y., Spicer, L. J. and Spicer, M. T. 2008. High-fat
diets promote insulin resistance through cytokine gene
expression in growing female rats. J. Nutr. Biochem.
19: 505-513.
31. Yan, E., Durazo, F., Tong, M. and Hong, K. 2007.
Nonalcoholic fatty liver disease: pathogenesis, identification, progression, and management. Nutr. Rev. 65:
376-384.
32. Yick, P. K., Poon, M. K. T., Ip, S. P. and Ko, K. M.
1998. In vivo antioxidant mechanism of ‘Sheng Mai
San’, A compound formulation. Pharm. Biol. 36:
189-193.
33. You, J. S., Huang, H. F., Chang, Y. L. and Lee, Y.
S. 2006. Sheng-mai-san reduces adriamycin-induced
cardiomyopathy in rats. Am. J. Chin. Med. 34: 295-305.
34. Chater, S., Abdelmelek, H., Douki, T., Garrel, C.,
Favier, A., Sakly, M. and Ben Rhouma, K. 2006. Exposure to static magnetic field of pregnant rats induces
hepatic GSH elevation but not oxidative DNA damage
in liver and kidney. Arch. Med. Res. 37: 941-946.
35. Fungwe, T. V., Cagen, L. M., Cook, G. A., Wilcox, H.
G. and Heimberg, M. 1993. Dietary cholesterol stimulates hepatic biosynthesis of triglyceride and reduces
oxidation of fatty acids in the rat. J Lipid Res. 34:
933-941.

48
Journal of Food and Drug Analysis, Vol. 19, No. 1, 2011

36. Yang, Y., Yin, C. Y., Yang, Y. and Zhao, S. 2004. Clinical study of effect of shengmai injection on insulin
resistance in patients with coronary heart disease. Acta
Acad. Med. Wuhan. 13: 363-364.
37. Zhang, Y. C., Chen, R. M., Lu, B. J., Zhao, M. H and
Rong, Y. Z. 2009. Influence of shengmai capsule on
recovery of living capacity in patients after myocardial
infarction. Chin. J. Integr. Med. 15: 333-336.
38. Liu, H., Yang, J., Du, F., Gao, X., Ma, X., Huang, Y.,
Xu, F., Niu, W., Wang, F., Mao, Y., Sun, Y., Lu, T., Liu,
C., Zhang, B. and Li, C. 2009. Absorption and disposition of ginsenosides after oral administration of Panax
notoginseng extract to rats. Drug Metab. Dispos. 37:
2290-2298.
39. Xu, M., Wang, G., Xie, H., Huang, Q., Wang, W. and
Jia, Y. 2008. Pharmacokinetic comparisons of schizandrin after oral administration of schizandrin monomer,
Fructus Schisandrae aqueous extract and Sheng-MaiSan to rats. J. Ethnopharmacol. 115: 483-488.

40. Ko, K. M. Ip, S. P., Poon, M. K., Wu, S. S., Che, C. T.,
Ng, K. H. and Kong, Y. C. 1995. Effect of a lignanenriched fructus schisandrae extract on hepatic glutathione status in rats: protection against carbon tetrachloride toxicity. Planta Med. 61: 134-137.
41. Guo, L. Y., Hung, T. M., Bae, K. H., Shin, E. M., Zhou,
H. Y., Hong, Y. N., Kang, S. S., Kim, H. P. and Kim,
Y. S. 2008. Anti-inflammatory effects of schisandrin
isolated from the fruit of Schisandra chinensis Baill.
Eur. J. Pharmacol. 591: 293-299.
42. Li, P. C., Mak, D. H. F., Poon, M. K. T., Ip, S. P. and
Ko, K. M. 1996. Myocardial protective effect of Sheng
Mai San (SMS) and a lignan-enriched extract of
Fructus Schisandrae, in vivo and ex vivo. Phytomedicine 3: 217-321.
43. Cheng, J. T. 2000. Review: Drug therapy in Chinese
traditional medicine. J. Clin. Pharmacol. 40: 445-450.

